We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Clinical Introduction
-
1. Frontotemporal dementia
- Prof. Bruce Miller
-
2. Parkinson disease
- Prof. Stanley Fahn
-
3. Atypical parkinsonian syndromes
- Dr. David Burn
-
4. Huntington's disease
- Prof. Roger Barker
- Neuroimaging
-
5. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
- Pathology, Genetic and Molecular Aspects (1)
-
6. A molecular understanding of Alzheimer's disease
- Prof. John Hardy
-
7. Neuropathology of neurodegenerative disorders
- Prof. Jillian Kril
-
9. Ubiquitination and Alzheimer related disorders
- Prof. John Mayer
- Pathology, Genetic and Molecular Aspects (2)
-
10. The molecular biology of Huntington's disease
- Prof. David C. Rubinsztein
-
11. Metals, oxidative stress and neurodegeneration
- Prof. Ashley Bush
- Latest Developments in the Field
-
12. Animal models of tauopathy
- Prof. David Westaway
-
13. Parkinson's disease and transplants
- Prof. Roger Barker
- Archived Lectures *These may not cover the latest advances in the field
-
14. Neuropathology of neurodegenerative disorders
- Prof. Jillian Kril
-
15. Motor neurone disease: molecular basis
- Prof. Kevin Talbot
-
16. Alzheimer's disease (AD)
- Prof. John Hodges
-
17. Frontotemporal dementia syndromes
- Prof. John Hodges
-
18. Motor neurone disease: clinical aspects
- Prof. Kevin Talbot
-
19. Neuro-imaging in dementia: using MRI in routine work-up
- Prof. Philip Scheltens
-
20. Prion diseases
- Prof. Pierluigi Gambetti
-
21. Mitochondrial disorders and neurodegeneration
- Prof. Anthony Schapira
-
23. Mutations in parkinsonian syndromes
- Dr. Andrew Singleton
-
25. Frontotemporal dementia
- Prof. Bruce Miller
Printable Handouts
Navigable Slide Index
- Intro slide
- Models of AD
- I - key facets of AD pathogenesis
- Pathogenic pathways
- A-beta peptide
- Neurofibrillary tangles
- AD genes
- A-beta derived by APP endoproteolysis
- BACE 1 is beta-secretase
- Gamma-cleavage of APP
- Gamma-secretase has many substrates
- Two ways for APP processing
- Tauopathies
- Simple pathogenic pathway for AD
- II - animal models of AD
- Why transgenic and why mice?
- Technical aspects of transgenesis
- Creation of transgenic APP mice
- Amyloid peptide in aging mice
- Morris water maze test
- Learning acquisition
- Creation of NFT-depositing mice
- Tangles, frontal cortex
- Astrocytic pathologies
- Encoded protein effects neuroanatomical position
- From A-beta to tau pathology
- III - new insights into pathogenesis
- Testing effects on A-beta
- Copper and A-beta
- Mutant mice with elevated copper
- Effects of copper on CSF A-beta
- Elevated copper and reduced plaque
- Conclusions
- Relationship between copper and pathogenesis
- Presenilin-1 transgenics
- Presenilin-2 transgenics
- PS1/PS2 and APP fragments
- IV - A-beta directed therapies
- AD vaccination studies
- Immunization with A-beta 1-42
- A-beta immunization of TgCRND8 mice
- Immunization 2000-2002
- A-beta antibodies inhibit fibril formation
- Epitope mapping of A-beta
- Immunotherapy of "Alzheimer" mice
- Pathogenic pathways
- AD pathogenesis scheme
- Acknowledgements
- References
Topics Covered
- Animal models and AD research
- Role in identifying pathological pathways, biomarkers and candidate therapies
- Design of models and associated technical parameters
- Process of transgenesis
- Developing mouse models for beta-amyloid precursor protein mutations
- TgCRND8 mice
- Transgenic approaches for investigating Tau mutations
- Exploring environmental modifiers of beta-amyloid pathobiology
- Candidate chemical risk-factor for sporadic AD
- Potential of ''smart'' beta-amyloid-directed interventions
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Westaway, D. (2007, October 1). Experimental therapies in Alzheimer's disease: the development and use of mouse models [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/JLBH5133.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. David Westaway has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Experimental therapies in Alzheimer's disease: the development and use of mouse models
A selection of talks on Methods
Hide